Full-Time

Associate Director

Posted on 3/11/2026

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$152k - $202k/yr

+ Short-Term Incentive + Long-Term Incentive (Equity)

New Haven, CT, USA

In Person

Category
Data & Analytics (2)
,
Required Skills
Sales
Data Governance
Data Analysis
Requirements
  • BS/BA degree in business or related discipline; MBA or advanced degree preferred
  • 8+ years of experience within the pharmaceutical, biotechnology, or consulting industries; launch experience strongly preferred
  • 5+ years of progressive experience in field/sales operations, CRM systems administration, incentive compensation, and/or consulting
  • Hands-on expertise designing, implementing, and assessing incentive plans for launch products
  • Strong analytical skills with the ability to frame business issues, apply quantitative methods, validate data, and creatively analyze information
  • A true team player—authentic, humble, collaborative, and able to support the team through the ups and downs of launch
  • Excellent interpersonal, oral, and written communication skills, including the ability to synthesize data for senior leadership
  • Deep experience with pharmaceutical data (e.g., IQVIA, SHA, patient claims, specialty pharmacy, hub data)
  • Strong business acumen, critical thinking, and problem-solving skills
  • Thrives in a fast-paced, minimally structured environment; comfortable with ambiguity
  • Ability to self-direct projects with minimal supervision
  • Experience managing vendor partners/consultants and leading project teams
  • Ability to travel to New Haven 3–4 times per month
Responsibilities
  • Lead a best-in-class incentive compensation function
  • Lead the committee and processes to compliantly design and document incentive plans
  • Design compliant incentive plans that appropriately motivate the field sales team
  • Develop tracking, attainment reconciliation, and payout calculation processes
  • Design timely and effective standardized incentive compensation reporting
  • Design and maintain Invivyd’s field-facing customer engagement model
  • Leverage subnational data and market knowledge to recommend optimal field structure and sizing
  • Design and deploy alignment processes to optimize territory effectiveness
  • Manage the field roster
  • Guide the compliant design of the CRM across Market Access, Sales, Medical Affairs, and Field Leadership
  • Monitor department performance against key KPIs and collaborate with Commercial Leadership on improvements
  • Assist Training & Development with the creation and implementation of systems training
  • Manage the commercial data environment vendor; act as business lead for Master Data Management and Data Warehouse
  • Ensure consistent and compliant collection, management, and usage of commercial data
  • Develop the commercial data management roadmap and overarching data strategy
  • Stand up the cloud-based data management environment and manage ongoing operations
  • Identify secondary data providers and facilitate data purchases
  • Ensure seamless, timely, and accurate ingestion, validation/QC, and integration of multiple internal and external data sources (specialty pharmacy, syndicated data, claims/EMR, CRM, Patient Services, etc.)
  • Partner with Commercial Analytics to develop tools and dashboards for key performance metrics
  • Assist in field targeting development and own operational execution
  • Serve as a thought partner to Commercial Operations and Field Leadership
  • Lead the POA cycle to ensure strategic alignment and coordinated execution
  • Champion intellectual agility and analytics to guide long-term strategy
  • Demonstrate managerial courage and sound decision-making
  • Display creativity and innovation in problem solving and process design
  • Serve on the cross-functional data governance team and help maintain high data quality
  • Oversee and execute a variety of ad hoc initiatives
  • Serve as HQ liaison for field personnel; develop and manage field communications; triage data/system inquiries; ensure field teams have the information needed to succeed

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA Q1 2026 revenue reached $13.7 million, up 22% year over year.
  • VYD2311 reached full enrollment in March 2026, with Q3 2026 data expected.
  • Cash of $184.2 million, plus April ATM proceeds, funds near-term development.

What critics are saying

  • VYD2311 depends on circulating variants at readout, making efficacy highly path-dependent.
  • COVID attack rates already slowed recruitment, threatening a commercial non-event.
  • Pipeline sprawl across measles, RSV, Lyme, and long COVID dilutes capital and focus.

What makes Invivyd unique

  • Invivyd combines evolutionary virology, predictive modeling, and antibody engineering.
  • PEMGARDA, pemivibart, won FDA EUA in March 2024 for COVID prophylaxis.
  • Michael Mina’s CMO appointment strengthens infectious-disease credibility and public-health positioning.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Invivyd who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-6%

2 year growth

-3%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.

INACTIVE